The Pharmaceutical Journal
Vol 271 No 7270 p488
11 October 2003

This article
Reprint
Photocopy

R & D News summary

Related websites
European College of Neuropsychopharmacology congress (www.ecnp.nl)

GABA-A agonist in trial for insomnia

Gaboxadol, a gamma-aminobutyric acid type A receptor agonist has entered a phase III clinical trial for treating insomnia. The trial is a randomised, double blind, multi-centre (100 sites in Europe and Canada) study in 650 patients with primary insomnia. In previous trials, sleep efficiency and night awakenings were found to be improved, with no signs of abuse potential compared with other hypnotic agents.

The Journal attended the European College of Neuropsychopharmacology congress courtesy of Eli Lilly